On Nov 07, major Wall Street analysts update their ratings for $CRISPR Therapeutics (CRSP.US)$, with price targets ranging from $30 to $95.
Evercore analyst Liisa Bayko maintains with a hold rating, and maintains the target price at $60.
TD Cowen analyst Tyler Van Buren maintains with a sell rating, and maintains the target price at $30.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $95.
Stifel analyst Benjamin Burnett maintains with a hold rating, and adjusts the target price from $59 to $53.
Truist Financial analyst Joon Lee maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $CRISPR Therapeutics (CRSP.US)$'s main analysts recently are as follows:
Crispr Therapeutics' third-quarter update underscored the CTX112 ASH abstract in B-cell malignancies, showcasing promising initial efficacy.
The journey for patients using Casgevy isn't brief, yet there are indications of demand starting to emerge. Notably, beyond the first patient infusion, 40 patients have completed at least one cell collection. Analysts remain cautious as they continue to evaluate the time needed to translate patient treatments into revenue and profitability. Looking ahead, the CTX112 ASH2024 abstract showed a 6-month complete response rate of 44% in a mixed lymphoma study. Further insight is anticipated upon full disclosure to better assess the drug's potential in the fields of oncology and autoimmune diseases.
Here are the latest investment ratings and price targets for $CRISPR Therapeutics (CRSP.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
